These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Prospective cohort study on the effects and tolerability of flutamide in patients with female pattern hair loss. Paradisi R; Porcu E; Fabbri R; Seracchioli R; Battaglia C; Venturoli S Ann Pharmacother; 2011 Apr; 45(4):469-75. PubMed ID: 21487083 [TBL] [Abstract][Full Text] [Related]
44. How actual is the treatment with antiandrogen alone in patients with polycystic ovary syndrome? Diamanti-Kandarakis E J Endocrinol Invest; 1998 Oct; 21(9):623-9. PubMed ID: 9856417 [No Abstract] [Full Text] [Related]
45. Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma. Schröder FH Prog Clin Biol Res; 1990; 359():93-103; discussion 105-7. PubMed ID: 2149460 [TBL] [Abstract][Full Text] [Related]
46. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892. Schröder FH; Whelan P; de Reijke TM; Kurth KH; Pavone-Macaluso M; Mattelaer J; van Velthoven RF; Debois M; Collette L; Eur Urol; 2004 Apr; 45(4):457-64. PubMed ID: 15041109 [TBL] [Abstract][Full Text] [Related]
47. [Theory and practice of daily prescription and gynecologic consultation for treatment of hyperandrogenism. Indications and contraindications]. Vexiau P Contracept Fertil Sex; 1999 Dec; 27(12):816-22. PubMed ID: 10676037 [No Abstract] [Full Text] [Related]
48. Total androgen blockade in the treatment of hormone-resistant metastasized prostate carcinoma. A literature review. Oosterlinck W; Mast P Acta Urol Belg; 1994 Apr; 62(1):67-71. PubMed ID: 8197932 [TBL] [Abstract][Full Text] [Related]
53. Hepatotoxicity induced by antiandrogens: a review of the literature. Thole Z; Manso G; Salgueiro E; Revuelta P; Hidalgo A Urol Int; 2004; 73(4):289-95. PubMed ID: 15604569 [TBL] [Abstract][Full Text] [Related]
54. [Hepatocellular carcinoma in a healthy liver possibly due to long-term use of cyproterone acetate]. Manfredi S; Lenfant L; Gresset AC; Bonnotte B; Lorcerie B; Chauffert B Presse Med; 2000 Nov; 29(36):1983. PubMed ID: 11149080 [No Abstract] [Full Text] [Related]
55. Effects of an oral contraceptive containing cyproterone acetate (Diane-35) on the symptoms, hormone profile, and ovarian volume of hirsute women with polycystic ovarian syndrome. Prelević GM; Puzigaća Z; Balint-Perić LA Ann N Y Acad Sci; 1993 May; 687():255-62. PubMed ID: 8323181 [No Abstract] [Full Text] [Related]
57. The place and the results of monotherapy. Bonnet P Acta Urol Belg; 1998 May; 66(2):11-5. PubMed ID: 9633120 [No Abstract] [Full Text] [Related]
58. Prolonged flare-up of testosterone after administration of a gonadotrophin agonist to a sex offender: an under-recognised risk? Huygh J; Verhaegen A; Goethals K; Cosyns P; De Block C; Van Gaal L Crim Behav Ment Health; 2015 Jul; 25(3):226-30. PubMed ID: 25851640 [No Abstract] [Full Text] [Related]